Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

Canadian Journal of Gastroenterology

Volumn 17, Issue 12, 2003, Pages 713-718

  Kiyici, Murat ^a   Gulten, Macit ^a   Gurel, Selim ^a   Nak, Selim Giray ^a   Dolar, Enver ^a   Savci, Gursel ^a   Adim, Saduman Balaban ^a   Yerci, Omer ^a   Memik, Faruk ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Atorvastatin; Nonalcoholic steatohepatitis; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIVER BIOPSY; LIVER FUNCTION TEST; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROLOGY; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0347917155     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/857869     Document Type: Article

References (13)

1. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
2. Diehl AM, Poordad F. Nonalcoholic fatty liver disease. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 7th edn. Philadelphia: WB Saunders, 2002:1393-401.
3. Bondestam S, Alanen A, Toikkanen S. Correlations of liver echo intensity with cytology and chemical measurements of fat, water and protein content in live burbots (Lota lota). Ultrasound Med Biol 1992;18:75-80.
4. Fishbein MH, Stevens WR. Rapid MRI using a modified Dixon technique: A non-invasive and effective method for detection and monitoring of fatty metamorphosis of the liver. Pediatr Radiol 2001;31:806-9.
5. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
6. Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin Proc 2000;75:733-9.
7. Day CP, James OFW. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998;114:842-5.
8. Harrison SA, Kadakia S, Torgerson S, Hayashi P. Vitamin E and vitamin C in the treatment of nonalcoholic steatohepatitis. A prospective, randomized, placebo-controlled clinical trial. A preliminary report. Gastroenterology 2002;122:A669.
9. Mehta K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: Pathogenesis and the role of antioxidants. Nutr Rev 2002;60:289-93.
10. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study. Hepatology 1996;23:1464-7.
11. Terasaki S, Nakanuma Y, Ogino H, Unoura M, Kobayashi K. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy. Am J Gastroenterol 1991;86:1194-9.
12. Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995;20:127-30.
13. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic effects of statins: Lipid reduction and beyond. J Clin Endocrinol Metab 2002;87:1451-8.